Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51012 | 0.87 | KMT2A (0.71) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL20830746 | 0.86 | KMT2A (0.61) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL13481158 | 0.85 | KMT2A (0.63) | MAPK1KMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL20830910 | 0.85 | TSHR (0.65) | MAPK1KMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL20830913 | 0.83 | MAPT (0.61) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL8673498 | 0.83 | KMT2A (0.65) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL6286657 | 0.83 | KMT2A (0.65) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL419486 | 0.83 | KMT2A (0.47) | MAPK1KMT2ASLC6A2SLC6A3TDP1 | |
| SCHEMBL50807 | 0.82 | KMT2A (0.73) | KMT2ASLC6A2SLC6A3TDP1LMNA | |
| SCHEMBL20830500 | 0.82 | TSHR (0.62) | MAPK1KMT2ASLC6A2SLC6A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-12 | — | — | US | disclosed |
| EP-3456713-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES | Japan Tobacco Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| US-6812235-B2 | 2-ACYLAMINO- BETA -ALANINE DERIVATIVES AND A PHARMACEUTICALLY ACCEPTABLE SALT, USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ASTELLAS PHARMA INC. (JP) | 2003-01-23 | — | — | US | disclosed |
| EP-1255748-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060813-A1 | BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018193-A1 | Beta-alanine derivatives and their use as receptor anatgonists | ARRB1, ADRB1, GLRB | MAPK1 1483/4885KMT2A 2770/4885SLC6A2 125/4885 |
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | MAPK1 184/4885KMT2A 3785/4885SLC6A2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.